Not a member? Sign Up

Reasons for Joining

    Address your challenges through knowledge sharing with peers from our global network of specialists.

    Benchmark your business initiatives with the who's who in the field.

    Hear from industry pioneers how to maximize ROI in today's challenging economy.

    And best of all It's FREE!
Sign in using your existing
Pharma IQ account
Username or Email:

Sign Up  |  Already a member? Sign In  |  Visit IQPC.com  
Pharma IQ


The SAT-EU Survey on Attitudes Towards Trial Site Selection in Europe

Contributor:  Pharma IQ Surveys
Posted:  09/26/2011  12:00:00 AM EDT  |  0

Rate this Article: (4.2 Stars | 10 Votes)
Tags:   SAT-EU Survey | trial site selection | clinical trial site | SAT EU Working Group | clinical trials | clinical trial | clinical trials Europe | Survey

While it is common wisdom in healthcare circles that speed of regulatory approvals is a key factor negatively influencing trial incidence,  the relative weight of multiple other criteria is simply not known. Information in this respect is neither in the medical literature, nor in health-care intelligence databases.

The SAT EU's Working Group Survey’s objective is to change this. We seek your help (1) to understand Industry's trial site selection criteria and (2) to rank potential improvements across three key domains - investigator, hospital and environment-driven criteria.

Can confidence in European research be restored via some simple solutions at the National level?  Is there something pragmatic which can be dealt with at the Site level?  Or are  there more complex issues to be addressed?  We would encourage you to complete this survey (approx. 10 min) to add your perspective to this question.

The SAT EU Working Group are seeking for input from anyone involved in multinational site selection from industry (Pharmaceutical, Biotech and Medical Device/Diagnostics) as well as CROs, and investigator driven multinational researchers. Please pass it on to other relevant people within your organisation as different disease entities may incur different issues. The last question of the survey lets you give us your e-mail, to inform you in advance of results publication:

The SAT-EU Survey

  Have Your Say
Rate this feature and give us your feedback in the comments section below

 



Pharma IQ Surveys Contributor:   Pharma IQ Surveys


* = required.

Not a member yet? Sign up
User Name:
Password:
You Should Check Out:


Be the first to leave a comment
Sign in or Sign up to post a comment

Advertisement

Events of Interest
Download Brochure

Please complete the information below to complete your download.

Please note: That all fields marked with an asterisk (*) are required.

First Name *
Last Name *
Job Title *
Company Name *
Email Address *
Telephone *
Country *
Where did you hear about us? *

I would like to receive information about sponsorship and exhibition opportunities

Yes, sign me up for the FREE Pharma IQ e-newsletter, including information on FREE Podcasts, Webinars, event discounts and online learning opportunities.

Advertisement

Recent Activity